Vestal Point Capital LP Purchases New Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Vestal Point Capital LP bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company's stock, valued at approximately $3,118,000. Vestal Point Capital LP owned about 0.15% of TransMedics Group at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in TMDX. Park Avenue Securities LLC lifted its holdings in shares of TransMedics Group by 3.8% in the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock worth $548,000 after acquiring an additional 322 shares during the last quarter. HB Wealth Management LLC raised its holdings in TransMedics Group by 49.2% in the 4th quarter. HB Wealth Management LLC now owns 8,149 shares of the company's stock valued at $508,000 after buying an additional 2,689 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $239,000. Cornerstone Wealth Management LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $231,000. Finally, Sachetta LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $40,000. Institutional investors own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 732 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the sale, the director now owns 12,134 shares of the company's stock, valued at $1,503,159.92. This trade represents a 5.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares of the company's stock, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.

TransMedics Group Trading Up 0.7%

TransMedics Group stock traded up $0.91 during mid-day trading on Friday, hitting $124.25. 443,082 shares of the stock were exchanged, compared to its average volume of 1,356,286. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The firm's fifty day simple moving average is $89.57 and its two-hundred day simple moving average is $77.29. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of 132.18 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. During the same quarter last year, the business earned $0.35 EPS. The company's revenue was up 48.2% compared to the same quarter last year. Analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

TMDX has been the subject of a number of research reports. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Piper Sandler reiterated an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Oppenheimer raised their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus price target of $126.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.